Amgen beats estimates but shares dip on biosimilar concerns
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
This report does not map to a usual set of affected companies.
Directly affected
- AMGN Amgen+13.5% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Amgen belongs to, so it often moves with news about it.
- GILD Gilead Sciences+16.4% 30d
Gilead Sciences is a peer of Amgen in biological products, (no diagnostic substances); rivals often move on the same news.
- MRNA Moderna+21.1% 30d
Moderna is a peer of Amgen in biological products, (no diagnostic substances); rivals often move on the same news.
- ARGX argenx SE-16.4% 16d
argenx SE is a peer of Amgen in biological products, (no diagnostic substances); rivals often move on the same news.
- RVMD Revolution Medicines
Revolution Medicines is a peer of Amgen in biological products, (no diagnostic substances); rivals often move on the same news.
- BIIB Biogen+15.1% 19d
Biogen is a peer of Amgen in biological products, (no diagnostic substances); rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| AMGN | -2.03% | +1.07% | base | after close | after close | after close | after close |
| XLV | -2.31% | +0.48% | base | after close | after close | after close | after close |
| GILD | -4.93% | +2.07% | base | after close | after close | after close | after close |
| MRNA | -6.29% | -2.97% | base | after close | after close | after close | after close |
| ARGX | -1.09% | -0.93% | base | after close | after close | after close | after close |
| RVMD | -2.84% | -1.45% | base | after close | after close | after close | after close |
| BIIB | -1.90% | +1.86% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Amgen beats estimates but shares dip on biosimilar concerns Yahoo Finance Singapore
Source: Yahoo Finance
This story
| Company | When | Move | Status |
|---|---|---|---|
| AMGN | three days earlier | +1.07% | final price |
| AMGN | five days earlier | -2.03% | final price |
| ARGX | three days earlier | -0.93% | final price |
| ARGX | five days earlier | -1.09% | final price |
| BIIB | three days earlier | +1.86% | final price |
| BIIB | five days earlier | -1.90% | final price |
| GILD | three days earlier | +2.07% | final price |
| GILD | five days earlier | -4.93% | final price |
| MRNA | three days earlier | -2.97% | final price |
| MRNA | five days earlier | -6.29% | final price |
| RVMD | three days earlier | -1.45% | final price |
| RVMD | five days earlier | -2.84% | final price |
| XLV | three days earlier | +0.48% | final price |
| XLV | five days earlier | -2.31% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. David J. Taylor bought Amgen (AMGN), worth $1,001 - $15,000 on 22 Sep 2026. That is 42 days before publication. Filed 1 Oct 2026. View the filing.
- Rep. David J. Taylor sold Amgen (AMGN), worth $1,001 - $15,000 on 26 Aug 2026. That is 69 days before publication. Filed 5 Sep 2026. View the filing.
- Sen. Sheldon Whitehouse sold Amgen (AMGN) (held by a spouse), worth $1,001 - $15,000 on 12 Aug 2026. That is 83 days before publication. Filed 2 Sep 2026. View the filing.
- Rep. Rohit Khanna sold Gilead Sciences (GILD) (held by a dependent child), worth $1,001 - $15,000 on 10 Aug 2026. That is 85 days before publication. Filed 4 Sep 2026. View the filing.
- Rep. Maria Elvira Salazar sold Moderna (MRNA), worth $1,001 - $15,000 on 24 Sep 2026. That is 40 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Moderna (MRNA) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Moderna (MRNA), worth $1,001 - $15,000 on 28 Aug 2026. That is 67 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Biogen (BIIB), worth $1,001 - $15,000 on 24 Sep 2026. That is 40 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Biogen (BIIB) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Kevin Hern sold Biogen (BIIB), worth $1,001 - $15,000 on 18 Aug 2026. That is 77 days before publication. Filed 1 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
How solid “Amgen beats estimates but shares dip on biosimilar concerns” looks
12 out of 100
“Amgen beats estimates but shares dip on biosimilar concerns” scores 12 out of 100. The score uses 1 sources.